Jiameng Wang, Yue Shang, Chenyang Wang, Dongdong Zhang, Han Li, Qian Yu, Lei Tao, Li Sun, Changjun Gao
Journal: Drug design, development and therapy 2026;20():593111
PMID: 42130899
BACKGROUND
Opioid-related adverse events are common with sufentanil-based patient-controlled intravenous analgesia after laparoscopic gastrointestinal cancer surgery in older adults. Oliceridine, a G protein-biased μ-opioid receptor agonist, may provide effective analgesia with fewer adverse events.
METHODS
In this single-center, randomized, double-blind, non-inferiority trial (Tangdu Hospital, Xi'an, China), patients aged ≥60 years undergoing elective laparoscopic radical resection for gastrointestinal malignant tumors were allocated 1:1 to postoperative patient-controlled intravenous analgesia containing oliceridine (0.4 mg/kg) or sufentanil (2 μg/kg), combined with ketorolac and tropisetron, for 48 hours. The primary endpoint was the cumulative area under the curve for resting 0-10 visual analogue scale pain scores over 0-48 hours. The non-inferiority margin was prespecified as 20% of the mean AUC in the sufentanil group (18.3 points), a threshold based on prior studies and deemed clinically acceptable.
RESULTS
Of 90 randomized patients, 88 received the study drug and were included in the analyses (44 per group); two patients were excluded as they never received the intervention. In the per‑protocol analysis, the cumulative resting pain area under the curve was 73.02±22.59 with sufentanil and 72.55±23.54 with oliceridine (between-group difference 0.48; 95% CI -9.30 to 10.26), meeting non-inferiority. A modified intention‑to‑treat analysis including all 88 treated patients yielded identical results, confirming robustness. Movement-evoked pain area under the curve was similar (difference 1.77; 95% CI -8.72 to 12.27). Respiratory depression occurred in 1/44 (2.27%) with oliceridine versus 8/44 (18.18%) with sufentanil, and hypotension in 5/44 (11.36%) versus 13/44 (29.55%).
CONCLUSION
In elderly patients undergoing laparoscopic gastrointestinal cancer surgery, oliceridine provided non-inferior analgesia to sufentanil while significantly lowering the incidence of respiratory depression and hypotension. These findings suggest that oliceridine may be a preferred opioid option for PCIA when respiratory and hemodynamic safety are critical concerns.
TRIAL REGISTRATION
ChiCTR2400090780.
© 2026 Wang et al.
Full Text Sources:
Research Materials:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.